Cargando…

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy

INTRODUCTION: The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown. AIM: The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darvishi-Khezri, Hadi, Kosaryan, Mehrnoush, Akbarzadeh, Rosseta, Aliasgharian, Aily, Fazli, Mehran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Medical Sciences of Bosnia and Herzegovina 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021158/ https://www.ncbi.nlm.nih.gov/pubmed/30061760 http://dx.doi.org/10.5455/medarh.2018.72.170-173

Ejemplares similares

Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
por: KOSARYAN, Mehrnoush, et al.
Publicado: (2019)

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015
por: Darvishi Khezri, Hadi, et al.
Publicado: (2016)

Moderate to severe liver siderosis and raised AST are independent risk factors for vitamin D insufficiency in β-thalassemia patients
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2020)

Ferritin thresholds for cardiac and liver hemosiderosis in β-thalassemia patients: a diagnostic accuracy study
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2022)

Amlodipine: Can act as an antioxidant in patients with transfusion‐dependent β‐thalassemia? A double‐blind, controlled, crossover trial
por: Darvishi‐Khezri, Hadi, et al.
Publicado: (2022)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
por: Ghazaiean, Mobin, et al.
Publicado: (2023)

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
por: Khezri, Hadi Darvishi, et al.
Publicado: (2016)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Zinc Supplementation in Adult Mechanically Ventilated Trauma Patients is Associated with Decreased Occurrence of Ventilator-associated Pneumonia: A Secondary Analysis of a Prospective, Observational Study
por: Hasanzadeh Kiabi, Farshad, et al.
Publicado: (2017)

Extramedullary Hematopoiesis Presenting as a Right Adrenal Mass in a Patient With Beta Thalassemia
por: Karami, Hossein, et al.
Publicado: (2014)

In Vitro Hb Production in B-thalassemia Patients Is Not a Predictor of Clinical Responsiveness to Hydroxyurea
por: MAHDAVI, Mohammad Reza, et al.
Publicado: (2017)

Fluorescent Detection of Methicillin Resistant Staphylococcus aureus by Loop-mediated Isothermal Amplification Assisted with Streptavidin-coated Quantum Dots
por: Aliasgharian, Aily, et al.
Publicado: (2022)

Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Relationship between beta-globin gene carrier state and insulin resistance
por: Bahar, Adele, et al.
Publicado: (2012)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

THU443 Acute Iridocyclitis Associated With Intravenous Zoledronic Acid
por: Ankireddypalli, Anvitha Reddy, et al.
Publicado: (2023)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
por: Chapurlat, Roland D
Publicado: (2009)

Treatment of Transient Osteoporosis of the Hip with Intravenous Zoledronate - A Case Report -
por: Seok, Hyun, et al.
Publicado: (2011)

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
por: Lewiecki, E Michael
Publicado: (2010)

Acute Iridocyclitis Associated With Intravenous Zoledronic Acid: A Case Report
por: Ankireddypalli, Anvitha R, et al.
Publicado: (2023)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
por: Gazoni, Fernanda Martins, et al.
Publicado: (2023)

Relationship between medical history and multiple sclerosis: A-case-control study
por: esfandiari, Fatemeh, et al.
Publicado: (2023)

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate
por: Al-Bogami, Mohammed M., et al.
Publicado: (2015)

Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs
por: Brewer, David John, et al.
Publicado: (2021)

ODP107 Oral Ulcerations, A Rare Side Effect of Intravenous Zoledronic Acid
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

Bound Variable Singular They Is Underspecified: The Case of All vs. Every
por: Moulton, Keir, et al.
Publicado: (2022)

Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture
por: Magaziner, Jay S, et al.
Publicado: (2014)

Prior administration of vitamin K(2) improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization
por: Zhao, Bin, et al.
Publicado: (2018)

Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea
por: Khavari, Maryam, et al.
Publicado: (2014)

Patient Safety and Efficacy of Metronidazole 1 g Intravenous Every 24 Hours
por: Desai, Alpa, et al.
Publicado: (2017)

Measurement bone mineral density (BMD) of patients with beta thalassemia
por: Abbasi, Sakineh, et al.
Publicado: (2018)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
por: Richhariya, Akshara, et al.
Publicado: (2012)

Call to action: a five nations consensus on the use of intravenous zoledronate after hip fracture
por: Johansen, Antony, et al.
Publicado: (2023)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

Diffuse Hepatic Calcifications in a Transfusion-Dependent Patient with Beta-Thalassemia: A Case Report
por: Saki, Forough, et al.
Publicado: (2013)

Histomorphometric Evaluation of Peri-Implant Bone Response to Intravenous Administration of Zoledronate (Zometa(®)) in an Osteoporotic Rat Model
por: Basudan, Amani M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tc0ts0fbr0ugvpt22qr1n7cggm